Can-Fite says Phase III namodenoson trial in advanced liver cancer advances under FDA, EMA guidance
Reuters2026/08/12 11:08- Can-Fite highlighted late-stage progress for two oral drug candidates, with pivotal Phase III programs underway for liver cancer and plaque psoriasis.
- No clinical results were reported; the liver cancer study is positioned to support future US and European filings if endpoints are met.
- Namodenoson is being tested in advanced hepatocellular carcinoma patients with Child-Pugh B7 cirrhosis under FDA and EMA regulatory guidance.
- Regulatory positioning includes FDA Fast Track for Namodenoson, with Orphan Drug designations in the US and Europe.
- Piclidenoson remains in Phase III development in moderate-to-severe plaque psoriasis, reinforcing the company’s late-stage pipeline focus.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
PMV Pharma issues warrants to buy 41,955,000 shares in $50.8 million offering
A cross-industry capacity scramble by Musk turns out to be a false alarm? Bernstein points out that SpaceX's self-research has minimal impact, maintains an "outperform" rating for Howmet (HWM.US)
Investment bank Bernstein has maintained its "Outperform" rating on aerospace precision parts giant Howmet Aerospace and raised its target price from $248 to $328.
AI dividends continue to be released! South Korea's exports in August maintain strong growth, with chip exports soaring by two times
Against the backdrop of continued strong demand for artificial intelligence (AI) driving chip exports and injecting robust momentum into the overall economy, South Korea's exports maintained strong growth in August.
Asiatel net loss widens to $1.29 million in 1H FY26; revenue rises 51% to $5.14 million
Crypto prices
More
